Table 5 A multivariate analysis of risk factors for COVID-19 severity

ARB/ACEI use before COVID- 19 diagnosis

1.05 (0.79–1.39)

0.759

0.99 (0.65–1.51)

0.9556

1 (0.63–1.58)

0.9851

ARB/ACEI use after COVID- 19 diagnosis

1.35 (0.83–2.2)

0.2206

0.92 (0.41–2.03)

0.8279

0.5 (0.17–1.44)

0.1978

Age group: 61–69

2.89 (2.13–3.93)

0.0685

3.48 (1.84–6.58)

0.0175

3.38 (1.53–7.46)

0.0033

Age group: 70–79

4.76 (3.47–6.53)

0.0002

7.48 (4.05–13.83)

0.0045

9.99 (4.76–20.99)

0.0008

Age group: ≥80

9.69 (6.9–13.59)

<.0001

24.66 (13.48–45.13)

<.0001

35.89 (17.31–74.43)

<.0001

Female

0.66 (0.53–0.82)

0.0001

0.52 (0.38–0.72)

<.0001

0.51 (0.36–0.73)

0.0002

Diabetes mellitus

1.46 (1.17–1.81)

0.0007

1.63 (1.17–2.27)

0.0038

1.79 (1.24–2.57)

0.0018

Cardiovascular disease

0.98 (0.62–1.56)

0.9361

0.93 (0.48–1.78)

0.8206

0.88 (0.43–1.77)

0.7089

Cerebrovascular disease

1.16 (0.87–1.54)

0.3179

1.08 (0.73–1.58)

0.7028

1.23 (0.82–1.84)

0.3121

Ischemic heart disease

0.99 (0.71–1.38)

0.9361

0.97 (0.62–1.53)

0.8956

0.93 (0.57–1.52)

0.7828

COPD

1.44 (0.76–2.69)

0.2611

0.92 (0.41–2.05)

0.8334

1.04 (0.46–2.34)

0.9345

Malignancy

1.17 (0.79–1.73)

0.4253

1.36 (0.82–2.24)

0.2299

1.45 (0.85–2.44)

0.17

Renal replacement

therapy

9.99 (3.82–26.1)

<.0001

4.13 (1.31–13.02)

0.0154

5.64 (1.71–18.58)

0.0045